Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MCH-1R CRISPR/Cas9 KO Plasmid (h): sc-402512
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MCH-1R CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MCH-1R genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MCH-1R Antibody (52-W7): sc-100327
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCH-1R CRISPR/Cas9 KO Plasmid (h) | sc-402512 | 20 µg | $397.00 |
Overview
MCHR1 encodes melanin-concentrating hormone receptor 1 (MCH-1R), a class A GPCR that binds MCH neuropeptide and regulates neuronal signaling involved in energy homeostasis, feeding behavior, arousal, and mood-related processes. Upon activation, MCH-1R couples primarily to Gi/o and Gq pathways to modulate intracellular cAMP, phospholipase C signaling, calcium flux, and downstream kinase cascades such as ERK/MAPK. Receptor activity influences synaptic transmission and neuroendocrine outputs across hypothalamic and limbic circuits. Dysregulation of MCHR1 signaling has been associated with metabolic phenotypes including obesity and insulin resistance, as well as neuropsychiatric features relevant to anxiety and depression research.
MCH-1R CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MCHR1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MCHR1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MCHR1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MCH-1R protein expression.
This CRISPR knockout system enables efficient generation of MCHR1-deficient cell models for investigation of MCH-1R signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MCHR1 exon(s) critical for MCH-1R function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MCHR1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MCH-1R CRISPR/Cas9 KO Plasmid (h) and MCH-1R CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MCHR1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MCH-1R HDR Plasmid (h) and MCH-1R HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MCHR1 homology arms to support homology-directed repair at defined MCHR1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.